Tetratherix Limited · ASX:TTX
Tetratherix — Investor Presentation (July 2025)
26 slides from Tetratherix's investor presentation, Jul 1, 2025
Slide 1: #anchoredbyscience
ASX:TTX #anchoredbyscience For personal use only
Slide 2: Important Information & Disclaimer
Disclaimer IMPORTANT INFORMATION & DISCLAIMER > USE OF THIS DOCUMENT You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the followi
Slide 3: Introduction
Introduction Will Knox Dr Ali Fathi CEO FOUNDER & CTO PRESENTING PRESENTING Will comes from a long history of medical and biological Ali is a world-renowned researcher and inventor of Tetramatrix technology development. Prior to Tetratherix, Will has worked for and has continued the development of t
Slide 4: Tetramatrix platform technology is the world's first biostealth fluid matrix
Introduction Tetramatrix™ platform technology is the world’s first biostealth fluid matrix A fully synthetic biomaterial used to optimise precision medicine. Compatible with minimally invasive administration techniques, with no foreign body reaction induced. Tetramatrix For personal use only Intelli
Slide 5: Why does the world need Tetratherix?
Introduction Why does the world need Tetratherix? The evolving dynamics of the global healthcare system is demanding innovative and cost-effective biomaterials Trends in healthcare delivery How does Tetramatrix address the problem? For personal use only Rising patient expectations Minimally invasive
Slide 6: Company History
History Company History Dental commercial Series A financing partnership commences Dermal clinical trial completed and and new polymer commenced First patent family First Skeletal second Skeletal configuration Invented Spacing program and safety results For personal use only Reconstruction Reconstru
Slide 7: Franchises
Franchises Derived products from the Tetramatrix platform technology span 3 large franchises and significant near-term commercial opportunities Bone Regeneration For personal use only Flowable bone graft Tissue Spacing Bone graft extender for extender for orthopaedic dental surgeries applications Sp
Slide 8: Commercial model
Commercial model TM Different clinical needs. Different market segments. Single Tetramatrix platform technology. Think of us like a SaaS business... The Tetramatrix biomaterial is our core ‘platform’ technology. We have Bone Tissue Spacing completed the foundational safety, efficacy and manufacturin
Slide 9: A capital light model with compounding revenue
Commercial model A capital light model with compounding revenue While we build our own production and R&D infrastructure, we avoid committing Pipeline capital on establishing multiple sales & distribution networks by utilising the Tissue Healing capabilities of our partners’ established teams. For p
Slide 10: Unit Economics
Unit Economics Not simply a science experiment. TetramatrixTM provides real world economics. Bone Regeneration Tissue Spacing Tissue Healing For personal use only TAM US$3.4bn US$1.3bn US$2.1bn Patient out- Reimbursed Patient out- Payer (US) of-pocket of-pocket We verify the final end user pricing a
Slide 11: Advance manufacturing and operations
Manufacturing Advance manufacturing and operations We have established advanced manufacturing in Sydney. To meet growing demand, a new facility is planned to be commissioned in 2026, with a modular design to allow us to quickly scale as needed. Our manufacturing process is: Manufacturing POD For per
Slide 12: Tegenix
For personal use only Tegenix
Slide 13: Tegenix | Bone Regeneration - Dental
Tegenix | Bone Regeneration - Dental A universal enabling solution to simplify complex oral & Partners dental procedures An innovative carrier designed to be mixed with a broad array of bone graft materials (BGMs) for dental and oral applications. For personal use only Key features Gentle press-fit
Slide 14: Tegenix | Market Seeding in 2026 with a Market Leader in Dentistry
Tegenix | Market Seeding in 2026 with a Market Leader in Dentistry Pilot Clinical Trials (2X) FDA Pathway Defined FDA Clearance H1 CY2026 Master Partnership Agreement Manufacturing Ready Market Seeding H2 CY2026 For personal use only Dry socket clinical trial n = >100 Canine Study Canine Study > (9
Slide 15: Tutelix
For personal use only Tutelix
Slide 16: Tutelix | Tissue Spacing - Oncology
| Tissue Spacing - Oncology Partners Safe & easy to use solution for more effective & simpler spacing in radiation oncology TutelixTM is intended for use as a spacer to reduce side effects to surrounding tissue during radiation therapy to treat prostate cancer. It is easily injected and is gradually
Slide 17: Tutelix | AU/US Clinical Trial in 2026
| AU/US Clinical Trial in 2026 HREC Approval Large Animal Studies Quality and Supply Agreement In CY2027 License Agreement + JV AU/ US Clinical Trial In 2026 FDA Clearance In CY2028 For personal use only Results Released for US KOL Program with early FDA-IND Clinical Trial (Pivotal, n=300, multicent
Slide 18: Optelex
For personal use only Optelex
Slide 19: Optelex | Tissue Spacing - Ophthalmology
Optelex | Tissue Spacing - Ophthalmology TM Partners Novel Synthetic reversible OVD for safe & simple application Optelex is a fully synthetic solution that maintains the volume and shape of the eye during surgery that can be removed via a simple saline wash. The product reduces the reliance of part
Slide 20: Optelex | First US Clinical Trial in 2027
Optelex | First I US Clinical Trial in 2027 TM Master Partnership Agreement Supply and License Agreement H2 CY2025 FDA Correspondence Mid CY2025 Invention and patent submission Clinical Trial CY2027 For personal use only FDA-IND Clinical Trial Results Released for Pivotal (Pivotal, n=300, multicentr
Slide 21: TetraDerm
For personal use only TetraDerm
Slide 22: TetraDerm | Tissue Healing
TetraDerm | Tissue Healing Partners The world’s first intraoperative scar prevention solution TetraDerm is the only flowable matrix that can be used intraoperatively to provide an internal cushioning effect to physically decrease mechanical tension and dead space, therefore reducing scar formation a
Slide 23: TetraDerm | Ongoing Clinical Data Readout
TetraDerm | Ongoing Clinical Data Readout Technical Validation FDA Correspondence Customer Need Identified Clinical Trial FDA Clearance 1H CY2029 Manufacturing Ready For personal use only Pilot Clinical Trial Clinical trial Cohort 1 n=8 Cohort 2 Initiation n=18 Cohort 3 Initiation n=27 Interim Repor
Slide 24: Near Term Milestones
Near Term Milestones Relentless execution with Regular newsflow in first 12 months post-listing Bone Regeneration Henry Schein Supply and FDA Studies on Licensing agreement Data Read-out from the FDA Submission FDA DENTAL Track FDA study execution Clearance For personal use only Master Partnership S
Slide 25: Strategic Licence Agreement signed with BioOptix Inc.
Strategic Licence Agreement signed with BioOptix Inc. Tetratherix and the New York-based ophthalmic company will develop and commercialise a novel ophthalmic viscoelastic device (OVD), built upon Tetratherix' polymer platform. Global OVD market is estimated to have a total addressable value of USD ~
Slide 26: For personal use only
For personal use only Copyright Tetratherix Pty Ltd. 2025 “Tetratherix”